



## Meeting with Medicines for Europe

### Meeting date and place

Meeting held on 14/12/2020 11:01 in Brussels

### Participating organisation(s) & representative(s)

[Art. 4.1 (b)]	[Art. 4.1 (b)] - MEDICINES FOR EUROPE (TRN: 48325781850-28)	<b>Participant.</b>
[Art. 4.1 (b)]	-- MEDICINES FOR EUROPE (TRN: 48325781850-28)	<b>Participant.</b>
[Art. 4.1 (b)]	-- MEDICINES FOR EUROPE (TRN: 48325781850-28)	<b>Participant, Requester.</b>
[Art. 4.1 (b)]	[Art. 4.1 (b)] - MEDICINES FOR EUROPE (TRN: 48325781850-28)	<b>Participant.</b>

### Main issues discussed

Medicines for Europe outlined that generic medicines account for 67% of the volume of prescription medicines in Europe.

Medicines for Europe underlined the importance of global supply chains for the sector, the role of the EU as supplier of medicines and active ingredients to third countries, and presented lessons learned from the COVID-19 pandemic.

Medicines for Europe expressed interest in the recently adopted EU Pharmaceuticals Strategy and in the Trade and Health initiative, stressing the importance for the sector to avoid the imposition of trade restrictive measures globally that would have negative impact on supply chains.

Medicines for Europe explained the key importance of well-performing procurement mechanisms to achieve a sustainable and competitive market for the sector.

### Directorate or unit

TRADE E/3

### Internal participants

[Art. 4.1 (b)]	TRADE E/3 [Art. 4.1 (b)] @ec.europa.eu	<b>Participant.</b>
[Art. 4.1 (b)]	TRADE E/3 [Art. 4.1 (b)] @ec.europa.eu	<b>Participant, Notetaker,</b>
[Art. 4.1 (b)]	TRADE D/1 [Art. 4.1 (b)]@ec.europa.eu	<b>Participant.</b>

### Author(s) of minutes

[Art. 4.1 (b)]

### Validator and validation date

[Art. 4.1 (b)] validated the minutes on 17/02/2021 09:25